SMAD2 and scleroderma: WGCNA analysis identified Smad2 as a hub gene in the treatment of scleroderma fibroblasts by ADSC supernatant (Figure 4A–C and Table S1), suggesting that the paracrine factors of ADSCs exerted antifibrotic effects by inhibiting the TGF-β1/Smad2 pathway.